95% of Indian cancer patients are treated without molecular testing. The signature is already on the H&E slide their lab produced. Hue is being built to read it — trained on Indian cohorts, starting in breast, lung, cervix, and colorectal.
The same reading — biomarker calls, regions of attention, confidence — surfaces where the work already happens. Pharma medical affairs identifying patients. R&D cohort scientists asking outcome-linked questions of Indian tissue. Pathology labs returning a co-signed companion-diagnostic report into the LIS.
Pharma medical-affairs programs run on patient yield. Hue surfaces biomarker-stratified patients from the H&E slide their lab already produced — at the granularity of a single case, inside the lab where the patient presented.
Indian cohorts are under-represented in every major cancer atlas. Hue is being built as a paired H&E + outcome-linked substrate of Indian cases — query-able by pharma R&D for cohort identification, real-world evidence, and discovery.
Biomarker calls — HER2, MSI, EGFR — validated against orthogonal molecular testing on Indian cohorts, returned as a co-signed report inside the existing LIS. Designed for CDSCO Class C IVD and ISO 13485 audit readiness.
For 150 years pathologists have read the headlines of an H&E slide — tissue architecture, grade, the obvious lesions. The molecular signature that determines what to do next has been in the same tissue, unread, because no one could see it at scale, in seconds, for the cost of a coffee. Hue is being built to read it — trained on Indian cohorts, validated against orthogonal molecular testing, co-signed by the pathologist.
Standard H&E, standard scanner, standard workflow. No new tissue, no new sample, no new procurement line. The reading meets the slide where it already exists.
A working pathologist sees one slide at a time. The reading is trained across millions of cells and the outcomes that followed them — to recognise the patterns no single eye can see at this scale, and to return a structured call with its confidence.
The treating pathologist co-signs every reading. Output flows back into the existing LIS as a structured report — biomarker calls, confidence, and the cases that warrant a confirmatory panel before treatment.
India produces twelve lakh H&E slides each year. The molecular calls that should follow them often do not — not because the tissue is missing, but because the workflow is. Hue is being built for that gap. Indian cohorts first; the figures below say why.
Indian cancer patients whose treatment is set without ever knowing the molecular signature of their disease.
Histopathology specimens read across Indian labs each year. The signal exists; the reading does not follow.
For HER2 / MSI / EGFR send-out testing from Indian centers — when it happens at all.
The reading scope follows India's cancer burden, not Western incidence patterns. Four indications are the initial scope; four more are on the roadmap.
A working manuscript on what India's slides know — and what gets translated, slowly, into a clinical decision. Preview chapters first.
A slide is, before anything else, a flat translation of three dimensions into one. The stains make that translation legible.
Where an inference engine should be least sure, and why an equivocal flag is itself a useful clinical signal.
For pharma medical affairs, R&D, and academic pathology — leave an email and a short note. Hue is pre-launch; we read every message before approving any pilot.